Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

BACKGROUND: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NC...

Descripción completa

Detalles Bibliográficos
Autores principales: Jänne, P A, Smith, I, McWalter, G, Mann, H, Dougherty, B, Walker, J, Orr, M C M, Hodgson, D R, Shaw, A T, Pereira, J R, Jeannin, G, Vansteenkiste, J, Barrios, C H, Franke, F A, Crinò, L, Smith, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506393/
https://www.ncbi.nlm.nih.gov/pubmed/26125448
http://dx.doi.org/10.1038/bjc.2015.215
_version_ 1782381675029725184
author Jänne, P A
Smith, I
McWalter, G
Mann, H
Dougherty, B
Walker, J
Orr, M C M
Hodgson, D R
Shaw, A T
Pereira, J R
Jeannin, G
Vansteenkiste, J
Barrios, C H
Franke, F A
Crinò, L
Smith, P
author_facet Jänne, P A
Smith, I
McWalter, G
Mann, H
Dougherty, B
Walker, J
Orr, M C M
Hodgson, D R
Shaw, A T
Pereira, J R
Jeannin, G
Vansteenkiste, J
Barrios, C H
Franke, F A
Crinò, L
Smith, P
author_sort Jänne, P A
collection PubMed
description BACKGROUND: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825). METHODS: Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations. RESULTS: In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations. CONCLUSION: Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity.
format Online
Article
Text
id pubmed-4506393
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45063932015-07-21 Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer Jänne, P A Smith, I McWalter, G Mann, H Dougherty, B Walker, J Orr, M C M Hodgson, D R Shaw, A T Pereira, J R Jeannin, G Vansteenkiste, J Barrios, C H Franke, F A Crinò, L Smith, P Br J Cancer Short Communication BACKGROUND: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825). METHODS: Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations. RESULTS: In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations. CONCLUSION: Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity. Nature Publishing Group 2015-07-14 2015-06-30 /pmc/articles/PMC4506393/ /pubmed/26125448 http://dx.doi.org/10.1038/bjc.2015.215 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Short Communication
Jänne, P A
Smith, I
McWalter, G
Mann, H
Dougherty, B
Walker, J
Orr, M C M
Hodgson, D R
Shaw, A T
Pereira, J R
Jeannin, G
Vansteenkiste, J
Barrios, C H
Franke, F A
Crinò, L
Smith, P
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
title Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
title_full Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
title_fullStr Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
title_full_unstemmed Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
title_short Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
title_sort impact of kras codon subtypes from a randomised phase ii trial of selumetinib plus docetaxel in kras mutant advanced non-small-cell lung cancer
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506393/
https://www.ncbi.nlm.nih.gov/pubmed/26125448
http://dx.doi.org/10.1038/bjc.2015.215
work_keys_str_mv AT jannepa impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT smithi impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT mcwalterg impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT mannh impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT doughertyb impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT walkerj impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT orrmcm impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT hodgsondr impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT shawat impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT pereirajr impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT jeanning impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT vansteenkistej impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT barriosch impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT frankefa impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT crinol impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer
AT smithp impactofkrascodonsubtypesfromarandomisedphaseiitrialofselumetinibplusdocetaxelinkrasmutantadvancednonsmallcelllungcancer

Ejemplares similares